Accurate Clinical Research

1. Novartis Pharmaceuticals Corporation $1,782,790 28 payments
2. AstraZeneca UK Limited $707,687 21 payments
3. AstraZeneca Pharmaceuticals LP $425,953 18 payments
4. Ucb SA $225,106 15 payments
5. Biogen, Inc. $53,660 1 payment
6. Amgen Inc. $46,988 4 payments
7. GlaxoSmithKline, LLC. $26,920 5 payments
8. Mallinckrodt Enterprises LLC $16,978 3 payments
9. Sun Pharmaceutical Industries Inc. $8,952 110 payments
10. E.R. Squibb & Sons, L.L.C. $4,031 2 payments

1. An Open-Label, Multi-Center Protocol for Patients Who Have Completed A Previous Novartis Sponsored Secukinumab Study and Are Judged By the Investigator to Benefit From Continued Secukinumab Treatment $626,497 3 payments
2. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $416,966 6 payments
3. A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) $397,966 3 payments
4. A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) $336,862 4 payments
5. The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre Randomised Double blind Placebo Controlled Phase 3 Extension Study to Characterise the Long term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus $252,738 14 payments
6. a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $179,337 2 payments
7. A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) $168,736 5 payments
8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $141,006 4 payments
9. An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab Infusion in Adults With Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) $117,198 2 payments
10. A 54 Week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo and Active Controlled, Parallel Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $62,718 3 payments

1. Other $1,153 17 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.